Vimarsana
Biggest News Aggregation in the World

Williamd Turner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Williamd Turner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Williamd Turner Today - Breaking & Trending Today

Vera Therapeutics, Inc. Announces Executive Changes - Vimarsana News

Vera Therapeutics, Inc. Announces Executive Changes

Vera Therapeutics, Inc. announced the appointments of two industry veterans to help lead the development of the company?s drug programs including its late-stage product candidate, atacicept, to treat...

Vera Therapeutics Announces Appointment of Industry - Vimarsana News

Vera Therapeutics Announces Appointment of Industry

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and...

-$0.95 Earnings Per Share Expected for Sierra Oncology, Inc. (NASDAQ:SRRA) This Quarter - Vimarsana News

-$0.95 Earnings Per Share Expected for Sierra Oncology, Inc. (NASDAQ:SRRA) This Quarter

Equities research analysts forecast that Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) will announce earnings of ($0.95) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.88) and the lowest estimate coming in at ($1.02). Sierra […]

Sierra Oncology (NASDAQ:SRRA) Rating Increased to Buy at Zacks Investment Research - Vimarsana News

Sierra Oncology (NASDAQ:SRRA) Rating Increased to Buy at Zacks Investment Research

Sierra Oncology (NASDAQ:SRRA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage currently has a $61.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside […]

HC Wainwright Downgrades Sierra Oncology (NASDAQ:SRRA) to Neutral - Vimarsana News

HC Wainwright Downgrades Sierra Oncology (NASDAQ:SRRA) to Neutral

Sierra Oncology (NASDAQ:SRRA – Get Rating) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Wednesday, The Fly reports. They currently have a $55.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 0.60% […]